Abstract: The present invention is a method for lowering serum levels of Lp(a), thereby reducing the risk of atherosclerotic disease. Specifically, the present invention comprises administering an effective amount of a N,S-diacyl-L-cysteine to a human or animal with elevated serum levels of Lp(a). The N,S-diacyl-L-cysteines comprise a compound selected from the group having the formula: ##STR1## wherein R is selected from the group consisting of hydrogen and an alkyl group containing 1 to 8 carbon atoms and R' is selected from the group consisting of acetyl, benzoly, thenoyl, 2-chromone-carbonyl and succinyl, and pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
March 13, 1991
Date of Patent:
May 19, 1992
Assignee:
Medicis Corporation
Inventors:
John W. Holaday, Jonah Shacknai, Leonard L. Mazur
Abstract: The present invention involves methods of inducing opiate-receptor antagonistic activity in a patient suffering from ischemic or traumatic central nervous system injury by administering to said patient an effective amount of an opiate-receptor antagonist having enhanced activity at the kappa-opiate receptor suitable to permit the induction of opiate-receptor antogonistic activity.
Abstract: A method of producing a dry whey protein powder fortified with naturally occurring polyclonal antibody IgG to preselected infectious intestinal disease antigens, primarily diarrhea-causing enterotoxigenic Escherichia coli bacteria bearing colonization factor antigens (CFA) I or II and heat labile toxins. The product is made by first immunizing a pregnant ungulate, such as a cow, by administration of antigens of the preselected disease. After parturition the milk from the ungulate is collected and maintained in its natural state. The milk is subjected to a standard cheese-making process which produces coagulated casein and whey. The antibody IgG is carried into the whey, which is concentrated and dried. The resulting dried protein powder contains the antibody. The product may be administered orally to living beings, both humans and other animals, to prevent contraction of the preselected disease and to treat bodies exposed to the disease.